Dissecting the Heterogeneity of Treatment Response in First-Episode Schizophrenia.
The Mental Health Centers for Intervention Development and Applied Research (CIDAR) program prioritized research to provide an evidence base for biomarker development. At the Zucker Hillside Hospital (ZHH), our CIDAR grant supported research on a comprehensive investigation of treatment response and outcome in first episode schizophrenia. Results provide evidence that baseline neuroimaging, neurocognitive, and genetic measures are significantly associated with clinical response to treatment, and that our currently available interventions can effectively treat aspects of psychotic illness, as well as potentially reduce comorbidity associated with illness. Future research may include combining modalities to more robustly predict response and identify treatment targets, as well as to further develop more effective intervention strategies for these devastating and disabling disorders.
AMalhotra@nshs.edu.
Anil K
AK
Malhotra
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology*; D015415:Biomarkers; D005500:Follow-Up Studies; D005625:Frontal Lobe / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D017072:Neostriatum / Q000187:drug effects* / Q000503:physiopathology; D009415:Nerve Net / Q000187:drug effects* / Q000503:physiopathology; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D055815:Young Adult
D014150:Antipsychotic Agents; D015415:Biomarkers
antipsychotic; biomarkers; cognition; efficacy; schizophrenia